Patritumab
Product Specifications
UNSPSC Description
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors[1].
Target Antigen
Akt; EGFR; ERK; PARP; Survivin
Type
Inhibitory Antibodies
Related Pathways
Apoptosis;Cell Cycle/DNA Damage;Epigenetics;JAK/STAT Signaling;MAPK/ERK Pathway;PI3K/Akt/mTOR;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/patritumab.html
Purity
98.95
Solubility
10 mM in DMSO
Smiles
[Patritumab]
References & Citations
[1]Kawakami H, et al. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget. 2014 Dec 15;5(23):11847-56.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99275/Patritumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99275/Patritumab-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
1262787-83-6
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
PB180336 500 mL
Earle's Balanced Salt Solution (EBSS), with calcium, magnesium, without phenol red
Ask
View Details 